Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 5 | 5 |
| 2001 | 0 | 16 | 16 |
| 2002 | 2 | 12 | 14 |
| 2003 | 1 | 16 | 17 |
| 2004 | 1 | 13 | 14 |
| 2005 | 1 | 34 | 35 |
| 2006 | 5 | 26 | 31 |
| 2007 | 4 | 39 | 43 |
| 2008 | 1 | 54 | 55 |
| 2009 | 4 | 63 | 67 |
| 2010 | 9 | 69 | 78 |
| 2011 | 9 | 97 | 106 |
| 2012 | 8 | 100 | 108 |
| 2013 | 9 | 131 | 140 |
| 2014 | 5 | 124 | 129 |
| 2015 | 5 | 126 | 131 |
| 2016 | 6 | 186 | 192 |
| 2017 | 7 | 155 | 162 |
| 2018 | 16 | 150 | 166 |
| 2019 | 11 | 177 | 188 |
| 2020 | 4 | 136 | 140 |
| 2021 | 9 | 111 | 120 |
| 2022 | 0 | 23 | 23 |
| 2023 | 0 | 11 | 11 |
| 2024 | 19 | 50 | 69 |
| 2025 | 3 | 8 | 11 |
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway. Cell Rep Med. 2025 Feb 18; 6(2):101941.
-
Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality. J Immunother Cancer. 2025 Feb 06; 13(2).
-
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. Nat Commun. 2025 Feb 01; 16(1):1248.
-
Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors. Breast Cancer Res. 2025 Jan 16; 27(1):8.
-
The EP3-ZNF488 Axis Promotes Self-Renewal of Glioma Stem-Like Cells to Induce Resistance to Tumor Treating Fields. Cancer Res. 2025 Jan 15; 85(2):360-377.
-
Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C-MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies. Cancer Res. 2025 Jan 15; 85(2):329-341.
-
PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models. Mol Cancer Ther. 2025 Jan 02; 24(1):56-68.
-
PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer. Mol Cancer Ther. 2025 Jan 02; 24(1):141-151.
-
Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer. Cancer Res Commun. 2025 Jan 01; 5(1):119-127.
-
The Combination of Tumor-targeting Salmonella typhimurium A1-R Plus the Autophagy-inhibitor Chloroquine Synergistically Eradicates HT1080 Fibrosarcoma Cells In Vitro and In Vivo. In Vivo. 2025 Jan-Feb; 39(1):102-109.